ScaleReady will provide sales, marketing, and application support for companies manufacturing cell and gene therapy products. Wilson Wolf's G-Rex cell culture technology, Fresenius Kabi's Lovo and upcoming Cue cell processing systems, and Bio-Techne's range of good manufacturing product (GMP) proteins, reagents, media, and gene editing technologies will be included in ScaleReady's manufacturing platform.

ScaleReady is owned equally by the three partners. Financial terms of the venture were not disclosed.

Bio-Techne opens GMP manufacturing facility
Bio-Techne has opened a 61,000-sq-ft good manufacturing practice (GMP) manufacturing facility in St. Paul, MN. The space will be dedicated to large-scale...

Bio-Techne rebrands genome engineering as part of R&D Systems portfolio
Bio-Techne has rebranded its cell and gene engineering product offer as part of its R&D Systems biotechnology brand.

Bio-Techne, Leica launch RNA probes for COVID-19 research
Bio-Techne and Leica Biosystems have announced the automation of RNAscope COVID-19 probes on Bond Rx, Leica's staining platform, for research use only....

Bio-Techne releases new SARS recombinant antibody
Bio-Techne has launched a SARS-CoV-1/2 spike receptor-binding domain LlamaBody recombinant antibody that blocks the virus from binding to the host receptor,...

Bio-Techne, Kantaro launch COVID-19 serology test
Bio-Techne and Kantaro Biosciences have launched COVID-SeroIndex, a quantitative SARS-CoV-2 immunoglobulin G antibody research-use only kit.